Emilio D Sulpizio1, Vikram Raghunathan2, Joseph J Shatzel2, Jevgenia Zilberman-Rudenko3, Tarin Worrest4, Brett C Sheppard4, Thomas G DeLoughery2. 1. Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon. 2. Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. 3. School of Medicine, Oregon Health and Science University, Portland, Oregon. 4. Department of Surgery, Oregon Health and Science University, Portland, Oregon.
Abstract
OBJECTIVE: Evans syndrome, the combination of immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) or autoimmune neutropenia, is associated with a high rate of relapsed/refractory disease. There are limited data on the efficacy of splenectomy for this condition. We reviewed patient outcomes after splenectomy for Evans syndrome compared to ITP at our institution. METHODS: We performed a retrospective analysis of patients who underwent splenectomy for autoimmune cytopenias over a 23-year period with the intention of comparing disease relapse rates after splenectomy in patients with Evans syndrome and in those with ITP. RESULTS: During the study period, 77 patients underwent splenectomy for ITP and seven underwent splenectomy for Evans syndrome. In the Evans cohort, splenectomy led to an 85.7% initial response rate with a 42.8% rate of relapse within one year and a long-term (one-year) response rate of 42.8%. In the ITP cohort, the initial response rate was 90.9% with a long-term response rate of 70.1%. CONCLUSION: Our data suggest that long-term remission rates after splenectomy are lower in adults with Evans syndrome compared to those with ITP, although splenectomy may still be an acceptable treatment for certain patients with Evans syndrome. Our findings underscore the need for further research and development of additional therapeutic strategies for this patient population.
OBJECTIVE:Evans syndrome, the combination of immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) or autoimmune neutropenia, is associated with a high rate of relapsed/refractory disease. There are limited data on the efficacy of splenectomy for this condition. We reviewed patient outcomes after splenectomy for Evans syndrome compared to ITP at our institution. METHODS: We performed a retrospective analysis of patients who underwent splenectomy for autoimmune cytopenias over a 23-year period with the intention of comparing disease relapse rates after splenectomy in patients with Evans syndrome and in those with ITP. RESULTS: During the study period, 77 patients underwent splenectomy for ITP and seven underwent splenectomy for Evans syndrome. In the Evans cohort, splenectomy led to an 85.7% initial response rate with a 42.8% rate of relapse within one year and a long-term (one-year) response rate of 42.8%. In the ITP cohort, the initial response rate was 90.9% with a long-term response rate of 70.1%. CONCLUSION: Our data suggest that long-term remission rates after splenectomy are lower in adults with Evans syndrome compared to those with ITP, although splenectomy may still be an acceptable treatment for certain patients with Evans syndrome. Our findings underscore the need for further research and development of additional therapeutic strategies for this patient population.
Authors: Susan Price; Pamela A Shaw; Amy Seitz; Gyan Joshi; Joie Davis; Julie E Niemela; Katie Perkins; Ronald L Hornung; Les Folio; Philip S Rosenberg; Jennifer M Puck; Amy P Hsu; Bernice Lo; Stefania Pittaluga; Elaine S Jaffe; Thomas A Fleisher; V Koneti Rao; Michael J Lenardo Journal: Blood Date: 2014-01-07 Impact factor: 22.113
Authors: Karen L Bride; Tiffaney Vincent; Kim Smith-Whitley; Michele P Lambert; Jack J Bleesing; Alix E Seif; Catherine S Manno; James Casper; Stephan A Grupp; David T Teachey Journal: Blood Date: 2015-10-26 Impact factor: 22.113